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PODIUM SESSION I: CANCER STUDIES
CN1
CERVICAL CANCER SCREENING PROGRAM IN THAILAND: 
ASSESSMENT OF SERVICE COVERAGE AND DETERMINANTS OF 
PROGRAM UPTAKE
Sirisamutr T, Butchon R, Putchong C, Praditsitthikorn N, Insrisawang L, Suksomboon N, 
Tantivess S, Teerawattnanon Y
Health Intervention and Technology Assessment Program (HITAP), Nonthaburi, Nonthaburi, 
Thailand
OBJECTIVES: In Thailand two approaches for cervical cancer screening, namely Pap 
smear and visual inspection with acetic acid (VIA), are introduced in the public sector. 
This study aims to assess the service coverage and the factors associating with screen-
ing test seeking behavior in two provinces, namely Chiangmai and Nakon Si Tham-
marat. METHODS: A cross-sectional household survey was conducted in 2009 in the 
two study provinces, among women aged 30–60 years old. A total of 1600 women 
were randomly selected by stratiﬁ ed four-stage sampling. Of these, 1577 were inter-
viewed (98% respondent rate). Descriptive statistics and logistic regression were used 
in the data analysis. RESULTS: This study suggests that the coverage rates of cervical 
screening tests in the past 5 years were relatively high; 76% in Chiangmai and 70% 
in Nakon Si Thammarat. In both provinces, Pap smear was more commonly intro-
duced than the VIA around two to three times. The most common reasons for not 
seeking screening tests was “the absence of symptoms,” followed by “the lack of time” 
and “feeling shy toward health workers.” A multivariate logistic regression analysis 
indicates that supporting and impeding factors of the screening service seeking behav-
ior were signiﬁ cantly associated with screening test. Women with the following char-
acteristics were more likely to seek the tests than others: age 40–50 years, agriculture 
occupation, child-bearing experience, cervical cancer history in family member, and 
ever exposing to the information regarding cervical cancer and screening tests. Mean-
while, respondents who were less likely than others to seek the screening services 
included cigarette smokers. CONCLUSIONS: There were several factors associating 
with the service seeking practices among women in these settings. In order to increase 
the service uptake, it is suggested that extensive education program concerning cervical 
cancer and screenings should be provided with the aim to abolish the misunderstand-
ings and increase awareness among target population. 
CN2
A SYSTEMATIC REVIEW AND META-ANALYSIS OF ADJUVANT 
CHEMOTHERAPY FOR STAGE III COLON CANCER
Lerdkiattikorn P1, Chaikledkaew U2, Kingkaew P3, Teerawattananon Y4
1Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, 
Mahidol University, Bangkok, Thailand; 2Division of Social and Administrative Pharmacy, 
Bangkok, Thailand; 3Health Intervention and Technology Assessment Program (HITAP), 
Ministry of Public Health, Nonthaburi, Thailand; 4Health Intervention and Technology 
Assessment Program (HITAP), Nonthaburi, Thailand
OBJECTIVES: This study aimed to assess clinical efﬁ cacy of three adjuvant chemo-
therapy regimens, namely 1) Mayo clinic regimen (5-ﬂ uorouracil and leucovorin, 5FU/
LV); 2) FOLFOX4 (oxaliplatin plus 5-FU/LV); and 3) oral capecitabine for treatment 
of patients with stage III colon cancer. METHODS: A systematic review of random-
ized controlled trials (RCTs), and meta-analysis of RCT of adjuvant chemotherapy 
for patients with stage III colon cancer were included by searching through the 
Medline and Cochrane databases. The clinical efﬁ cacy studies of three adjuvant che-
motherapy regimens on improving survival outcomes of patients with stage III colon 
cancer were included. Indirect or mixed-treatment comparison meta-analysis with ﬁ x 
effect model was applied to combine results of several studies. The meta-analysis was 
carried out using Bayesian approach and WinBUGS14 software program. The 
summary efﬁ cacy of adjuvant chemotherapy were presented as odds ratio (OR) and 
its 95% conﬁ dence interval (CI). To test the variation of study outcomes between 
studies, heterogeneity test was also applied. RESULTS: Total of 714 abstracts were 
reviewed and four eligible studies related to adjuvant chemotherapy for patients with 
stage III colon cancer were included in the meta-analysis. Two studies compared oral 
capectitabine with 5-FU/LV, while one study compared FOLFOX4 with 5-FU/LV. 
Indirect comparison was used to compare FOLFOX 4 and oral capecitabine. When 
compared to 5-FU/LV, FOLFOX4 and oral capecitabine could signiﬁ cantly reduce the 
risk of death by 23% (OR = 0.77, 95% CI = 0.68–0.86) and 16% (OR = 0.84, 95% 
CI = 0.72–0.98), respectively. Moreover, the OR of mortality among patients treated 
by oxaliplatin plus 5-FU/LV was 0.92 (95% CI = 0.76–1.11) compared to capecitabine. 
CONCLUSIONS: Of three regimens for patients with adjuvant chemotherapy stage 
III colon cancer, FOLFOX4 could signiﬁ cantly yield the longest patient survival, fol-
lowed by capecitabine and 5-FU/LV. However, FOLFOX4 did not signiﬁ cantly reduce 
mortality events compared with capecitabine. 
CN3
QUALITY OF LIFE IN ADVANCED CANCER PATIENT—COMPARISON 
OF PATIENT-REPORTED OUTCOME (PRO) AND PROXIES ASSESSMENT
Choi J1, Miyashita M2, Kim B3
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea; 
2Tohoku University School of Health Sciences, Sendai, Japan; 3Hanyang University, Seoul, 
South Korea
OBJECTIVES: While Quality Of Life (QOL) in subjects suffering from advanced 
cancer patient has been studied using a variety of generic or speciﬁ c instruments, only 
very few studies have analyzed the agreement between patients and proxy ratings on 
patients’ QOL. The objective of this study was to compare PRO of quality of life and 
proxy assessment using EORTC QLQ PAL-15. METHODS: We administered the 
EORTC QLQ PAL-15 to 32 patients and their own family, nurse and doctor, respec-
tively as proxies of patient. The QLQ PAL-15 is a 15-item shortened version of the 
EORTC QLQ-C30 cancer-speciﬁ c health-related quality of life measure consisting of 
two functional scale (physical and emotional), seven symptom scale (fatigue, pain, 
nausea and vomiting, dyspnea, appetite loss, insomnia, constipation), and single-item 
scale to assess quality of life. The analyses focused on intraclass correlation coefﬁ cients 
(ICCs) to comparing the ICC 95% lower conﬁ dence interval with critical value 0.70 
and Pearson’s correlation coefﬁ cients. RESULTS: Agreement between patients and 
proxies on the scales was excellent for physical function (ICC = 0.889) and fatigue 
(ICC = 0.739). Emotional function, emesis, pain, appetite loss, constipation, constipa-
tion and quality of life scale was fair agreement (ICC range from 0.471 to 0.739). 
Dyspnea (ICC = 0.301) and insomnia (ICC = 0.097) was poor agreement between 
PRO and proxies assessment. There were higher correlation with family than other 
proxies with patient in emotional function (r = 0.791, P < 0.001), insomnia (r = 0.774, 
P < 0.001), nausea and vomiting (r = 0.646, P < 0.001), appetite loss (r = 0.638, P < 
0.001), dyspnonea (r = 0.402, P < 0.005). There were higher correlation with nurse 
than other proxies with patient in physical function (r = 0.791, P < 0.001) and con-
stipation (r = 0.540, P < 0.001). There were higher correlation with doctor than other 
proxies in pain(r = 0.494, P < 0.001), and fatigue (r = 0.406, P < 0.005). CONCLU-
SIONS: The agreement between PROs and proxies assessment in QOL assessment is 
different by symptom and function. Family caregiver were more agreement than nurse 
and doctor. We need to paid attention to proxy assessment more carefully. 
CN4
CAN WE CORRECTLY TARGET HIGH-COST THERAPIES? THE 
DIAGNOSTIC ACCURACY OF HISTOLOGY IN DIFFERENTIATING 
BETWEEN SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL 
LUNG CANCER
Paech D, Weston A
Health Technology Analysts Pty Ltd, Sydney, NSW, Australia
OBJECTIVES: The importance of identifying non-small cell lung cancer (NSCLC) 
histological subtype has increased recently because of the need to target high cost 
therapeutic agents to the correct patient population. This systematic review was 
undertaken to examine the diagnostic accuracy of histology in differentiating between 
subtypes of NSCLC, speciﬁ cally the ability to differentiate squamous from non-
squamous histology. METHODS: A systematic literature search was undertaken to 
identify studies that evaluated the reproducibility of histologic diagnosis by patholo-
gists in their reporting of NSCLC subtypes. Studies were screened systematically using 
a priori deﬁ ned eligibility criteria. The National Health and Medical Research Council 
(NHMRC) diagnostic levels of evidence were applied, and quality assessed using the 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. Data were 
extracted and re-analyzed to permit comparison of agreement in non-squamous and 
squamous cell carcinoma via 2 × 2 tables. Pooled diagnostic performance measures 
including sensitivity, speciﬁ city, positive predictive value (PPV), negative predictive 
value (NPV) were calculated, with the PPV being considered the most relevant indica-
tor for the treating clinician. RESULTS: Out of 1480 articles identiﬁ ed through the 
literature search, seven were eligible for inclusion. The PPV of non-squamous histology 
was consistently high in each individual study with only a small amount of variation 
between studies. This resulted in a very high pooled PPV of 95.3% (94.0–96.3%) for 
the primary meta-analysis. CONCLUSIONS: The high individual and pooled PPV 
suggests that pathologists can reliably differentiate between non-squamous and squa-
mous NSCLC. This is important in guiding oncologist decision-making in choosing 
the most appropriate therapy for their patients. It is also signiﬁ cant from a purchaser 
perspective; because it will limit cost leakage from prescriptions mistakenly given 
outside the drugs approved indication (i.e., to the incorrect NSCLC patient group) 
due to misdiagnosis. 
PODIUM SESSION I: HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT1
EARLY ALERT SYSTEMS FOR NEW PHARMACEUTICALS—DO THEY 
HAVE AN IMPACT ON PHARMACEUTICAL REIMBURSEMENT 
DECISIONS?: A CROSS-NATIONAL COMPARISON
Hiller JE, Mundy L
University of Adelaide, Adelaide, South Australia, Australia
OBJECTIVES: With the successful incorporation of horizon scanning (HS) into HTA 
it has been postulated that HS of pharmaceuticals may inform pharmaceutical assess-
ment for public reimbursement in Australia. This paper intends to examine the role 
of HS for pharmaceuticals, the effect that HS may have had on the introduction of 
new drugs onto the health market, and assess whether HS for pharmaceuticals would 
improve access to new drugs in Australia and New Zealand. METHODS: The 
EuroScan database of HS agencies was searched for pharmaceuticals assessed in 2004 
by the National Horizon Scanning Centre (UK) and the Canadian Agency for Drugs 
and Technologies in Health. Time taken to licensing and  public reimbursement or 
access approval, if given, in the UK, Canada, Australia and New Zealand was ascer-
tained. RESULTS: Of 21 drugs identiﬁ ed by HS in 2004 by the NHSC, 11 received 
licensing approval and the National Institute for Health and Clinical Excellence has 
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delivered guidance on ﬁ ve of these, with three being recommended. In Australia, 10/21 
of these drugs had licensing approval and seven underwent assessment by the Phar-
maceutical Beneﬁ ts Advisory Committee. All seven received approval for listing on the 
public reimbursement scheme. Similarly, CADTH assessed 16 drugs by HS in 2004. 
Of these, 10 received licensing approval but only one gained approval to be listed by 
the Canadian Expert Drug Advisory Committee. Of these 16 drugs, 14 had licensing 
approval in Australia and 12 underwent assessment by the PBAC, with only two being 
declined approval for listing on the public reimbursement scheme. CONCLUSIONS: 
The current process of pharmaceutical assessment appears to give Australian patients 
timely access to publicly funded pharmaceuticals and that the introduction of HS for 
new and emerging drugs would neither decrease the time to access for patients or 
better inform policymakers than the system already in place. 
HT2
COST-EFFECTIVENESS OF INTERVENTIONS FOR REDUCING ROAD 
TRAFFIC INJURIES RELATED TO DRIVING UNDER THE INFLUENCE OF 
ALCOHOL
Ditsuwan V1, Veerman JL2, Bertram M2, Vos T2
1Thaksin University, Phatthalung, Thailand; 2The University of Queensland, Brisbane, 
Queensland, Australia
OBJECTIVES: To determine the cost-effectiveness of interventions to reduce road 
trafﬁ c injuries caused by driving under the inﬂ uence of alcohol in Thailand. 
METHODS: This study used generalized cost-effectiveness analysis. We calculated 
costs from a health sector perspective. The time-horizon for intervention implementa-
tion was 1 year with health outcomes measured over a lifetime. The model covers 
road trafﬁ c crash victims who were injured, disabled, or died due to road trafﬁ c 
crashes. We obtained proportions of alcohol-related crashes, by age and sex of the 
victims, from the Thai Injury Surveillance system. Random breath testing (RBT), 
selective breath testing (SBT) and mass media campaigns compared to a “do nothing” 
scenario. We calculated intervention costs and cost offsets of prevented treatment costs 
in 2004 Thai Baht and measured beneﬁ ts in terms of disability-adjusted life-years 
(DALYs) averted. RESULTS: The study found similar incremental cost-effectiveness 
ratios (ICERs) of SBT and RBT. SBT was cost saving while RBT had an ICER of 1000 
Baht (95% uncertainty interval [UI]: cost saving to 7200) per DALY averted if cost-
offsets are included. The ICER of mass media campaigns was 8300 (95% UI: cost 
saving to 45,100). A combination of SBT or RBT and mass media campaigns is very 
cost-effective compared to a willingness to pay threshold of one times gross domestic 
product per capita (110,000 Baht) in 2004. CONCLUSIONS: The result shows all 
interventions are cost-effective, but wide variation is seen in the uncertainty ranges. 
Sobriety checkpoints and mass media campaigns reduce burden of alcohol-related RTI 
by 38,000 to 41,000 DALYs. 
HT3
COST-EFFECTIVENESS OF BLOOD PRESSURE LOWERING WITH A 
FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE IN TYPE 2 
DIABETES MELLITUS: A TRIAL-BASED ANALYSIS USING THE ADVANCE 
STUDY
Clarke PM1, Glasziou P2, Alexander J3, Chalmers J4, Patel A5
1University of Sydney, Sydney, NSW, Australia; 2University of Oxford, Oxford, Oxfordshire, 
UK; 3University of Queensland, Brisbane, Australia; 4George Institute, Sydney, Australia; 
5George Institute, Sydney, Australia
OBJECTIVES: To determine the cost-effectiveness of routine administration, irrespec-
tive of blood pressure, of a ﬁ xed-dose combination of perindopril and indapamide to 
patients with Type 2 diabetes. METHODS: Prospective cost-effectiveness analysis 
within a 20 country randomized trial of 11,140 patients with Type 2 diabetes random-
ized to perindopril plus indapamide or placebo. We calculated cost per death averted 
at 4.3 years average follow-up and estimated cost per life-year gained by extrapolation. 
RESULTS: The ADVANCE trial showed a 14% relative risk reduction in all cause 
mortality (P < 0.03) and an 18% relative risk reduction (0.8% absolute reduction) in 
cardiovascular mortality (P < 0.03). Hospital admissions for coronary heart disease 
and coronary revascularization were reduced by 5%. Per patient perindopril-indap-
amide cost AUS$1368, but reduced total hospitalization costs by AUS$410 and other 
medication costs (mainly other blood pressure lowering drugs) by AUS$332. Quality 
of life, measured by the EQ-5D, was 0.80 (on a 0–1 scale); with no difference between 
groups. Absolute reduction in all-cause mortality was 1.1%, giving a cost per life saved 
of AUS$49,200, and life-time extrapolation estimated a cost per life-year saved of 
AUS$8,470 (discounted at 3%). CONCLUSIONS: The combination of perindopril 
and indapamide in patients with type 2 diabetes reduces all-cause mortality and 
appears cost-effective. 
HT4
HEALTH TECHNOLOGY ASSESSMENT DATABASE IN THAILAND
Kapol N1, Lochid-amnuay S2, Chalongsuk R2, Maitreemit P2, Sribundit N2, Amrumpai Y2
1Silpakorn University, Nakorn Pathom, Thailand; 2Silpakorn University, A. Muang, Nakhon 
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BACKGROUND: Health technology assessment is a pivotal tool to assist policymak-
ers to decide whether a health technology is efﬁ cient. However, the accessibility of 
health technology assessment information in Thailand is problematic. Attempts to 
develop Thai health technology assessment database has been raised. The database 
aims to increase accessibility and utility to policymakers, researchers and practitioners. 
From January 2008, Thai health technology assessment database has been available 
online at http://www.db.hitap.net. OBJECTIVES: The objectives of this study are to 
determine current contents of the database and evaluate the usefulness of the database. 
METHODS: A review of the Thai health technology assessment database was con-
ducted to determine the main characteristics of studies, the number of included studies, 
the number of database members, and number of visitors. Moreover, the use of the 
database was evaluated by an electronic mail survey to 260 website members. 
RESULTS: By the end of 2009, the database consisted of 732 articles including three 
types of studies, 155 full economic evaluation studies, 471 randomized control trials 
studies and 106 quality of life studies. The number of database members is 711. The 
number of visitors increases from 1123 to 1717 hits per month in 2008 and 2009, 
respectively. For the survey results, of 260 members, 41 respondents (15.77%) replied 
to the electronic mail survey. Most of them used the database for studying and/ or 
conducting a research. The usefulness of the database was found most in 65.86% of 
respondents. CONCLUSIONS: Thai health technology assessment database provided 
useful information to users. However, some types of studies should be included to 
support potential users’ needs. Moreover, the registration system for the members 
should be further improved to follow up and effectively disseminate information to 
users. 
PODIUM SESSION I: INFECTIOUS DISEASE STUDIES
IN1
ECONOMIC AND CLINICAL BURDEN OF PNEUMOCOCCAL DISEASES 
AND ACUTE OTITIS MEDIA IN TAIWAN: A NATIONWIDE 
POPULATION-BASED DATABASE ANALYSIS
Chang CJ1, Wang PC2, Huang YC3, Wu BS4
1Chang Gung University, Taoyuan, Taiwan; 2Cathay General Hospital, Taipei, Taiwan; 3Chang 
Gung Memorial Hospital, Taoyuan, Taiwan; 4National Yang-Ming University, Taipei, Taiwan
OBJECTIVES: Streptococcus pneumonia can cause invasive diseases such as menin-
gitis and bacteremia, and noninvasive diseases such as pneumonia and acute otitis 
media (AOM), leading to high morbidity and mortality in infants and the elderly. 
Limited data are available for the burden of these diseases in Taiwan. This study 
investigates economic and clinical burden of pneumococcal diseases and AOM in 
Taiwan. METHODS: A retrospective population-based National Health Insurance 
Reimbursement Database (NHIRD) study was performed to estimate the incidence 
and direct medical costs of pneumococcal meningitis/bacteremia/pneumonia and 
AOM from 2002 to 2007 from healthcare provider perspective, including only NHI-
covered costs. RESULTS: The incidence of pneumococcal meningitis is 0.1 per 
100,000 and highest at age <1 (2.4 per 100,000) and decreases with age. The incidence 
of pneumococcal bacteremia is 0.9 per 100,000 with peak at 7.1 per 100,000 at age 
75 and above, followed by 3.7 at age 2 and 3. The incidence of pneumococcal pneu-
monia is 165.1 per 100,000 with peak at 1060.9 per 100,000 at age 75 and above, 
followed by 1230.7 per 100,000 at age 1, followed by 1076.9 per 100,000 at age 2. 
The AOM incidence is 2,729.1 per 100,000 with peak at 23,078.8 per 100,000 at 
age 1, and high in children group (9,641 per 100,000 at age 12 and below). Annually, 
120 deaths are estimated to cause by pneumococcal diseases. The total annual medical 
cost is US$110,886,546. The annual cost for pneumococcal meningitis is US$193,021, 
mainly for inpatients (US$189,794). The annual cost for pneumococcal bacteremia is 
US$744,573, mainly for inpatients (US$732,282). For pneumococcal pneumonia, the 
total annual cost is US$74,029,821 mainly for inpatients (US$66,353,242). For AOM, 
the annual cost is US$35,919,131, US$18,059,540 for inpatients and US$17,859,590 
for out-patients. CONCLUSIONS: Our study shows huge burden of pneumococcal 
diseases and AOM in Taiwan. Prevention of these diseases will help reduce clinical 
and economic burden. 
IN2
COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR 
TUBERCULOSIS CONTROL PROGRAMS IN THAILAND
Hunchangsith P, Barendregt JJ, Vos T, Bertram M
The University of Queensland, Brisbane, Queensland, Australia
OBJECTIVES: To evaluate the cost-effectiveness of different strategies to control 
tuberculosis (TB) in Thailand. METHODS: Strategies included directly observed treat-
ment (DOT) by a health worker, community member, or family member, and a mobile 
phone “contact-reminder” system, compared to self-administered treatment (SAT). 
Cost-effectiveness analysis was undertaken using a decision tree model, which had 
three stages of treatment; initial treatment, re-treatment, and multi-drug resistant TB 
(MDR-TB) treatment. Costs (2005 international dollars: I$) were calculated based on 
treatment periods and treatment outcomes. Health outcomes were estimated over the 
lifetime of smear-positive pulmonary TB patients in disability-adjusted life-years 
(DALYs). Both costs and health outcomes were discounted at 3%. RESULTS: Cost-
effectiveness results did not clearly indicate a preference for any of the interventions 
analyzed. Although the median cost-effectiveness ratio for each DOT intervention was 
favorable, the uncertainty ranges surrounding the health beneﬁ ts were wide, including 
a sizeable probability that SAT could lead to more health gain than DOT strategies. 
The health gain in DALY for family-member DOT was 9400 DALY (95% uncertainty 
interval −7200 to 25,000), for community-member DOT was 13,000 (−21,000 to 
37,000) and health-worker DOT was 7900 (−50,000 to 43,000). There were cost-
savings (from less re-treatment or MDR-TB treatment) associated with family-member 
DOT (–I$9 million (–I$12 million to –I$5 million)) as the trial treatment failure rate 
was signiﬁ cantly lower than for SAT. The mobile phone reminder system was not 
cost-effective, as the mortality rate in the small trial of this intervention was much 
